+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Addiction Treatment Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • April 2023
  • Region: Global
  • Expert Market Research
  • ID: 5780684
The global addiction treatment market size attained a value of about USD 6.8 billion in 2022. The market is further expected to grow at a CAGR of 6.1% during the forecast period of 2023-2031 to reach nearly USD 11.7 billion by 2031 driven by the increasing prevalence of addiction across the globe.

Addiction Treatment Market: Introduction

Addiction treatment refers to the process of helping individuals overcome their dependence on drugs or alcohol. Addiction is a chronic disease that affects the brain, and it can be difficult to overcome without professional help. Addiction treatment programs typically include a combination of behavioural therapies, medication-assisted treatment, support groups, and other services designed to address the physical and psychological aspects of addiction. The ultimate goal of addiction treatment is to help individuals achieve long-term recovery and improve their overall quality of life.

Key Trends in the Addiction Treatment Market

Some of the key trends in the global addiction treatment market include:

  • Increased Focus on Holistic Treatment: There is a growing trend towards the use of holistic treatment approaches that focus on treating the whole person rather than just the addiction. This includes incorporating elements such as mindfulness, yoga, nutrition, and exercise into treatment programs
  • Telehealth and Digital Solutions: With the ongoing COVID-19 pandemic, there has been a significant increase in the use of telehealth and digital solutions for addiction treatment. This trend is likely to continue as it provides greater accessibility and convenience for patients
  • Medication-Assisted Treatment: There has been a growing use of medication-assisted treatment (MAT) in addiction treatment. MAT involves the use of medications to help manage withdrawal symptoms and cravings, and has been shown to be effective in increasing treatment retention and reducing relapse rates
  • Personalized Treatment Plans: There is a shift towards more personalized treatment plans that take into account individual patient needs and preferences. This includes tailoring treatment approaches based on factors such as age, gender, and co-occurring mental health conditions
  • Increased Access to Treatment: There is a growing recognition of the need to increase access to addiction treatment for all individuals, regardless of their socio-economic status or geographic location. This has led to an increase in the availability of low-cost and free treatment options, as well as the expansion of telehealth services

Addiction Treatment Market Segmentations

Market Breakup by Treatment Type

Medications

  • Bupropion
  • Varenicline
  • Acamprosate
  • Disulfiram
  • Naltrexone
  • Methadone
  • Buprenorphine
  • Nicotine Replacement Products
  • Others

Counseling and Behavioral Therapies

  • Cognitive -Behavioral Therapy
  • Multi-Dimensional Therapy
  • Motivational
  • Others
  • Detoxifications
  • Others

Market Breakup by Addiction Type

  • Alcohol Addiction Treatment
  • Tobacco/Nicotine Addiction Treatment
  • Opioid Addiction Treatments
  • Other Addictions

Market Breakup by Route of Administration

  • Oral
  • Parentals
  • Others

Market Breakup by Treatment Centres

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Rehabilitation Centres
  • Others

Market by Treatment Channel

  • Public
  • Private

Market by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Addiction Treatment Market Scenario

The addiction treatment market has been growing in recent years due to various factors such as increasing awareness of addiction as a disease, rising substance abuse cases, and government initiatives to combat drug abuse. The market is primarily driven by the increasing prevalence of addiction, especially opioid addiction, and the rising demand for addiction treatment services. The report also suggests that North America is expected to hold the largest share of the addiction treatment market, owing to the high prevalence of addiction cases in the region, followed by Europe and the Asia Pacific.

Competitor Landscape

The report gives an in-depth analysis of the key players involved in the addiction treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd
  • Abbott
  • Medtronic
  • BD
  • Johnson & Johnson Services, Inc
  • GSK Plc
  • Bayer AG
  • Zimmer Biomet
  • Stryker Corporation
  • Homology Medicines, Inc
  • Novartis AG
  • Pfizer Inc
  • JCR Pharmaceuticals Co., Ltd
  • Sangamo Therapeutics
  • AVROBIO, Inc
  • REGENXBIO Inc
  • CAN bridge Life Sciences Ltd
  • Denali Therapeutics

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Addiction Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Addiction Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Addiction Epidemiology (2016-2031)
5.3 Europe Addiction Epidemiology (2016-2031)
5.4 Asia Pacific Addiction Epidemiology (2016-2031)
5.5 Latin America Addiction Epidemiology (2016-2031)
5.6 Middle East and Africa Addiction Epidemiology (2016-2031)
6 Global Addiction Treatment Market Overview
6.1 Global Addiction Treatment Market Historical Value (2016-2022)
6.2 Global Addiction Treatment Market Forecast Value (2023-2031)
7 Global Addiction Treatment Market Landscape
7.1 Addiction Treatment: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
8 Addiction Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Addiction Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Addiction Treatment Market Segmentation
11.1 Global Addiction Treatment Market by Treatment Type
11.1.1 Market Overview
11.1.2 Medications
11.1.2.1 Bupropion
11.1.2.2 Varenicline
11.1.2.3 Acamprosate
11.1.2.4 Disulfiram
11.1.2.5 Naltrexone
11.1.2.6 Methadone
11.1.2.7 Buprenorphine
11.1.2.8 Nicotine Replacement Products
11.1.2.9 Others
11.1.3 Counseling and Behavioral Therapies
11.1.3.1 Cognitive -Behavioral Therapy
11.1.3.2 Multi-Dimensional Therapy
11.1.3.3 Motivational
11.1.3.4 Others
11.1.4 Detoxifications
11.1.5 Others
11.2 Global Addiction Treatment Market by Addiction Type
11.2.1 Market Overview
11.2.2 Alcohol Addiction Treatment
11.2.3 Tobacco/Nicotine Addiction Treatment
11.2.4 Opioid Addiction Treatments
11.2.5 Other Addictions
11.3 Global Addiction Treatment Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parentals
11.3.4 Others
11.4 Global Addiction Treatment Market by Treatment Centres
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Specialty Clinics
11.4.4 Homecare Settings
11.4.5 Rehabilitation Centres
11.4.6 Others
11.5 Global Addiction Treatment Market by Treatment Channel
11.5.1 Market Overview
11.5.2 Public
11.5.3 Private
11.6 Global Addiction Treatment Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Addiction Treatment Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Addiction Treatment Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Addiction Treatment Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Addiction Treatment Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Addiction Treatment Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Addiction Treatment Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Takeda Pharmaceutical Company Limited
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 F. Hoffmann-La Roche Ltd.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Abbott
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Medtronic
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Abbott
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 BD
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Johnson & Johnson Services, Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 GSK Plc.
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Bayer AG
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Zimmer Biomet
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Stryker Corporation
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Homology Medicines, Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Novartis AG
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Pfizer Inc.
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 JCR Pharmaceuticals Co., Ltd.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Sangamo Therapeutics
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 AVROBIO, Inc.
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 REGENXBIO Inc.
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 CANbridge Life Sciences Ltd.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Denali Therapeutics
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Addiction Treatment Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Medtronic
  • Abbott
  • Bd
  • Johnson & Johnson Services, Inc.
  • Gsk plc.
  • Bayer AG
  • Zimmer Biomet
  • Stryker Corporation
  • Homology Medicines, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Jcr Pharmaceuticals Co. Ltd.
  • Sangamo Therapeutics
  • Avrobio, Inc.
  • Regenxbio Inc.
  • Canbridge Life Sciences Ltd.
  • Denali Therapeutics

Methodology

Loading
LOADING...

Table Information